Ardsley, N.Y.-based Acorda Therapeutics, a biotechnology company, announced that it has acquired two neuropathic pain management assets from NeurogesX in San Mateo, Calif., a specialty pharmaceutical company that develops non-opioid, pain management therapies.
The company acquired Qutenza, an FDA-approved pain patch for the management of neuropathic pain associated with postherpetic neuralgia. It also acquired NP-1998, a prescription strength capsaicin topical solution, which being assessed for the treatment of neuropathic pain and is ready for phase three of its trial.
More Articles on Pain Management:
Sussex Pain Relief Center Breaks Ground on New Location in Delaware
Florida's Lake County to Extend Pain Management Clinic Ban
Arizona Pain Specialists Opens New Location